Clinical Trials Browser

Phase 1/2 × monalizumab × Other hematologic neoplasm × Clear all

NCT02557516 2019-12-17

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Phase 1/2 Terminated

22 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell